Minkonti (Mirabegron)

Minkonti (mirabegron) acts on the β3‑adrenergic pathway to improve bladder storage function.

• Overactive bladder: increases bladder capacity and reduces urgency episodes.
• Urinary urgency: lessens the sudden need to void.
• Urinary frequency: decreases the number of daily voids.

• Mirabegron selectively activates β3‑adrenergic receptors located in the detrusor smooth muscle of the bladder. This activation triggers a cascade that raises intracellular cyclic AMP, leading to relaxation of the detrusor muscle during the storage phase, thereby increasing functional bladder capacity and reducing involuntary contractions.

Adverse reactions may occur with mirabegron therapy.

Common Side Effects

• Hypertension: elevated blood pressure readings.
• Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
• Urinary tract infection: dysuria or cloudy urine.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Dry mouth: decreased salivation.

Serious or Rare Side Effects

• Urinary retention: difficulty initiating or maintaining urine flow.
• Tachycardia: rapid heart rate requiring monitoring.
• Angioedema: swelling of face, lips or throat.
• Severe hypertension: blood pressure markedly above normal limits.
• Myocardial infarction: rare cardiac ischemic events.
• Acute renal failure: sudden loss of kidney function.

Before initiating mirabegron, several safety considerations should be reviewed.

• Blood pressure monitoring: check baseline and periodic readings.
• Renal function assessment: evaluate creatinine clearance in patients with kidney disease.
• Hepatic function review: adjust use in moderate to severe liver impairment.
• Concomitant antihypertensive therapy: anticipate possible reduction in antihypertensive effect.
• Caution in uncontrolled hypertension: avoid initiation until blood pressure is controlled.
• Store below 25°C: keep in the original pack, protect from moisture.

Mirabegron may interact with other medicines through metabolic pathways or pharmacodynamic effects.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise plasma levels.
• Antimuscarinic agents combined with mirabegron: heightened risk of urinary retention.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs (e.g., ACE inhibitors, beta‑blockers): mirabegron may attenuate blood‑pressure‑lowering effect.
• Digoxin: potential increase in serum digoxin concentrations.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce mirabegron efficacy.
• NSAIDs: additive effect on blood pressure elevation.